Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.38 USD | +1.79% | -4.67% | +15.23% |
04-18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
04-18 | Verastem Oncology Announces Executive Changes | CI |
Sales 2024 * | - | Sales 2025 * | 30.71M 2.46B | Capitalization | 237M 19B |
---|---|---|---|---|---|
Net income 2024 * | -130M -10.41B | Net income 2025 * | -117M -9.37B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.73 x |
P/E ratio 2024 * |
-2.21
x | P/E ratio 2025 * |
-3.15
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.43% |
1 day | +1.79% | ||
1 week | -4.67% | ||
Current month | -20.51% | ||
1 month | -19.07% | ||
3 months | -18.58% | ||
6 months | +38.96% | ||
Current year | +15.23% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 63 | 31/12/10 |
Daniel Calkins
DFI | Director of Finance/CFO | 37 | 30/11/18 |
Jonathan Pachter
CTO | Chief Tech/Sci/R&D Officer | 66 | 30/06/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 67 | 02/05/17 |
John Johnson
BRD | Director/Board Member | 66 | 22/04/20 |
Michael Kauffman
CHM | Chairman | 60 | 25/11/12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 9.38 | +1.79% | 42,669 |
25/04/24 | 9.215 | -1.02% | 71,213 |
24/04/24 | 9.31 | -3.12% | 79,258 |
23/04/24 | 9.61 | -1.33% | 101,636 |
22/04/24 | 9.74 | -1.02% | 95,499 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.23% | 237M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VSTM Stock